NuCana plc ADR (NCNA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Baillie Gifford's Strategic Acquisition of NuCana PLC Shares
On September 1, 2024, Baillie Gifford (Trades, Portfolio), a prominent investment management firm, expanded its portfolio by acquiring 917,600 shares of NuCana PLC, a UK-based biopharmaceutical company. This transaction, executed at a price of $3.66 per share, marks a significant addition to Baillie Gifford (Trades, Portfolio)'s holdings, reflecting a strategic move within the biotechnology sector.
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.
NuCana plc ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 2 | $2.8 | $3.9 | $1.1 | 39.29% |
| AAL Avraham A. Levitan Glass Jacobson Investment Advisors LLC | 15,000 | $69,600 | $29,250 | -$40,350 | -57.97% |
NuCana plc ADR Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LG Leland Gershell Oppenheimer | -423.2 | $217,381.89 | $825.23 | $216,556.66 | 99.62% |
NuCana plc ADR (NCNA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NuCana plc ADR ever had a stock split?
NuCana plc ADR Profile
| Biotechnology Industry | Healthcare Sector | Hugh Stephen Griffith CEO | NASDAQ (CM) Exchange | 67022C304 CUSIP |
| GB Country | 20 Employees | - Last Dividend | 11 Aug 2025 Last Split | 28 Sep 2017 IPO Date |
Overview
NuCana plc is a clinical-stage biopharmaceutical company dedicated to the development of innovative medicines for treating cancer patients. Founded in 1997 and undergoing a rebranding from NuCana BioMed Limited in August 2017, the company has its headquarters in Edinburgh, United Kingdom. NuCana leverages its proprietary ProTide technology to advance the field of cancer treatment. This technology is aimed at transforming existing chemotherapy agents and nucleoside analogs into more effective medicines, thereby addressing the limitations of traditional nucleoside analogs. Through the enhancement of these compounds, NuCana's approach is designed to produce significantly higher concentrations of anti-cancer metabolites within cancer cells. The company's commitment to improving patient outcomes has led it to establish a collaboration agreement with Cardiff ProTides Ltd for the discovery and design of potential drug candidates.
Products and Services
- NUC-3373
A next-generation compound derived from the nucleoside analog 5-fluorouracil, NUC-3373 is being developed to optimize the efficacy and safety profile of cancer treatment. NuCana is conducting a multifaceted clinical trial program for NUC-3373, which includes a Phase 1b/2 study in patients with metastatic colorectal cancer, a Phase 2 trial for second-line treatment of advanced colorectal cancer, and a Phase 1b/2 trial aimed at treating patients with advanced solid tumors and lung cancer. The goal of NUC-3373 development is to overcome the limitations of 5-fluorouracil and deliver enhanced concentrations of anti-cancer metabolites directly to cancer cells.
- NUC-7738
This ProTide transformation of 3'-deoxyadenosine represents another facet of NuCana's robust oncology pipeline. NUC-7738 is intended to provide a novel treatment option for patients with advanced solid tumors. The development of NUC-7738 is propelled by its ongoing Phase 2 study, which is part of a broader Phase 1/2 clinical trial designed to assess its efficacy and safety in a cancer care setting. Through the innovative application of ProTide technology, NUC-7738 seeks to harness the potential of nucleoside analogs in a novel way, targeting the unmet needs of patients facing advanced stages of cancer.
